Fertility financing 101: How to afford IVF
IVF costs can range from $12,000 to over $41,000 per cycle, depending on location and medication needs.
Unexpected costs, such as emergency visits, additional medication and travel, can also significantly increase the total expense.
Personal loans, HELOCs and credit cards can help bridge the gap between insurance coverage and the total cost.
Consider clinic success rates, less expensive fertility treatments and funding options before committing to a treatment plan.
The financial burden of in vitro fertilization (IVF) can be significant for couples struggling with infertility. While insurance may cover some aspects of treatment, many expenses remain out-of-pocket.
Understanding the different financing options can help provide insight into what to consider before taking on debt to fund fertility treatments.
The cost of IVF varies widely depending on the clinic, location and the specific procedures required. For Denny Ceizyk, a senior writer for the loans team at Bankrate, IVF was a $70,000, six-year journey from 1996 to 2002 before he and his wife welcomed their child. Adjusted for inflation, this comes out to be roughly $144,000 in 2025.
For Ceizyk, IVF costs ranged from $6,000 for a basic cycle in Arizona to $20,000 for a more advanced procedure in New Jersey. This included specialized treatments, medications and travel expenses. In 2025 dollars, this is $12,340 to $41,150.
'Most of the expense was for 'transfer' day when the embryos were transferred into my wife after being grown for several days,' Ceizyk shared. 'Unexpected costs included infertility drugs, which weren't always accounted for in the initial price sheet. We had to scramble to buy extra medication if things weren't progressing as planned.'
These wide-ranging costs highlight why it's critical to plan ahead. Even with insurance or clinic discounts, IVF is a significant financial undertaking. Understanding the full scope of potential expenses — but upfront and unexpected — can help you make informed decisions and avoid surprise bills along the way.
When choosing a fertility treatment, know that IUI (intrauterine insemination) is generally a less invasive, less costly procedure.IVF (in vitro fertilization) is typically more successful, though it is more complex and costly.
This table breaks down each type of IVF cost in major U.S. cities and regions based on data collected by FertilityIQ.. These costs include consultation fees, medication and common add-on treatments like ICSI and PGT-A. They reflect out-of-pocket costs and may not include hidden expenses like additional cycles, monitoring or travel.
Type of cost
Atlanta
Boston
Chicago
Los Angeles
New Jersey
New York City
San Francisco
SeattleConsultation$282$352$438$320$408$408$410$312Medication$5,000$5,000$5,000$5,000$5,000$5,000$5,000$5,000ICSI$1,687$1,280$1,750$1,763$1,725$2,500$1,891$900PGT-A$4,800$5,111$5,425$5,475$5,000$5,881$5,202$4,700IVF$11,363$8,267$11,666$13,325$10,866$9,705$12,246$12,450
Total IVF cost
$23,132
$20,010
$24,279
$25,883
$22,999
$23,494
$24,749
$23,363
Several states have laws requiring insurers to offer or provide coverage for infertility diagnosis and treatment. These mandates vary widely in scope, from comprehensive IVF coverage to limited diagnostic testing.
Understanding which states require coverage — and what kind — can help you better anticipate costs and explore all available options.
States with infertility insurance coverage laws
Arkansas
California
Colorado
Connecticut
Delaware
Hawaii
Illinois
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Montana
New Hampshire
New Jersey
New York
Ohio
Rhode Island
Texas
Utah
Washington, D.C.
Those who have insurance through a state exchange may also have IVF coverage. Some states, such as California and Texas, require that insurance companies within their state offer IVF coverage. To find out the insurance coverage requirements where you live, check the National Conference of State Legislatures (NCSL), which details IVF coverage requirements for many states.
Bear in mind, however, that the extent of health insurance coverage for IVF will vary significantly depending on the health insurance company and even the state you live in. For instance, in New Jersey health insurers must provide coverage for the diagnosis and treatment of infertility. This mandate includes covering in vitro fertilization.
In contrast, Louisiana's laws state that while insurers are prohibited from excluding coverage for the diagnosis and treatment of conditions that result in infertility, insurers are not required to cover fertility drugs, in vitro fertilization or other assisted reproductive techniques.
Before pursuing IVF, it's essential to consider the full scope of potential expenses.
Doctor's visits and medical exams.
Medications for home use.
Genetic testing.
Surgical procedures and embryo transfers.
Aftercare and follow-up appointments.
'There's a price sheet that lays everything out pretty clearly with each cycle,' notes Ceizyk. 'But unexpected costs, such as extra blood tests or emergency room visits due to the side effects of the egg-growing drugs, can add up quickly.'
For many couples, financing IVF requires tapping into multiple sources of funding. Beyond traditional loans and credit cards, there are other ways to manage the high cost of IVF. These options may offer tax advantages, more flexibility or even financial relief through grants or clinic partnerships.
Using personal savings is one of the most straightforward ways to pay for IVF treatment. It allows you to avoid debt, interest charges and loan approval processes — all of which can add stress during an already emotional time. If you have the funds available, tapping your savings may be the most cost-effective route.
On the flip side, fertility treatments can cost tens of thousands of dollars, and these expenses can quickly deplete an emergency fund or delay other financial goals. If you plan to use savings for IVF, consider creating a dedicated fertility fund separate from your general savings.
Money tip: Some clinics offer discounts for patients paying upfront with cash, so be sure to ask about savings incentives if you're using your own funds or have the money from a loan available.
If you have access to an FSA or HSA through your insurance plan, you can use those tax-advantaged funds to pay for eligible IVF expenses. While coverage varies, these accounts typically allow you to use pre-tax dollars for medications, lab work, diagnostic testing and portions of treatment. Be sure to check your plan's specific rules regarding treatment options and how costs are paid.
Several nonprofit organizations offer grants to individuals and couples undergoing fertility treatments. Programs like the Cade Foundation, Baby Quest Foundation and Hope for Fertility provide financial assistance to help cover the cost of IVF. While grants are highly competitive and often require an application and personal story, they can significantly offset costs for recipients.
Personal loans are increasingly popular for covering the high costs of fertility treatments, and lenders may offer IVF loans or allow you to use a general purpose personal loan to pay for treatment costs. Many lenders offer loans up to $50,000 — and a select few offer loans up to $100,000 — that can be repaid over the course of five to seven years.
According to Haiyan Huang, Chief Credit Officer at Prosper, personal loans provide flexibility and can be a more predictable alternative to credit cards.
'Personal loans offer predictable monthly payments and fixed interest rates, which can be much lower than credit card rates,' Huang explains. Additionally, she advises borrowers to carefully assess their repayment capacity.
'Ensure the loan fits comfortably within your overall budget, and consider any associated fees or interest rates. Maintaining a good credit score is crucial to securing more favorable terms.'
If you plan to cover multiple cycles of IVF treatments, a personal loan may be the best choice outside of savings and grants. They are unsecured, so you won't risk your home or other assets when you borrow, and personal loan rates start at a current low of 6.49 percent.
If you anticipate needing multiple cycles for IVF, a home equity loan or home equity line of credit may be useful. These products allow you to tap into the value of your home, and very few have specific restrictions on how you use your funds. Your home is the collateral for the loan, however, so default could lead to foreclosure. Before you apply, be sure to weigh the risks against the benefits to ensure this is the right funding route for your treatment.
Ceizyk initially covered costs using income from his sales job but eventually had to take out a $15,000 home equity line of credit (HELOC) and utilize credit cards to cover additional expenses.
'I liked the HELOC because it had the lowest payment, and we had no plans to sell our house any time soon,' Ceizyk says. 'Same deal with credit cards. I didn't want to have a fixed monthly payment and needed the flexibility of minimum payments if I had to shell out a thousand dollars for drugs in a given week.'
A credit card may be a good choice for surprise expenses that come with IFV, but you likely won't have enough of a credit limit to cover the cost of an IVF cycle. That said, you can choose to use credit cards to cover part or all of your IVF costs, especially if you are able to qualify for a 0 percent introductory APR. This can give you time to pay off the balance without interest — but only if you're confident you can repay it before the promotional period ends. Otherwise, you could face interest rates of 25 percent or higher.
For those considering a personal loan or other financing options, Ceizyk shared key advice: 'First, find out the full extent of coverage you have with your employer or if you're in a state where some level of IVF coverage is mandated. Second, review the success rates at your clinic to ensure you're making the most of your financial investment.'
IVF can be an emotionally and financially taxing journey. Exploring financing options, from HELOCs and credit cards to personal loans with, can provide critical support in managing these costs. By understanding the full financial impact and planning ahead, prospective parents can navigate their IVF journey more confidently and effectively.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Analysts unveil bold forecast for Alphabet stock despite ChatGPT threat
Analysts unveil bold forecast for Alphabet stock despite ChatGPT threat originally appeared on TheStreet. You typed in a question and clicked a few links, and Google could get paid if you landed on an ad. For years, that simple cycle helped turn Google into a trillion-dollar titan. But now, that model is under threat. 💵💰💰💵 AI-powered chatbots like OpenAI's ChatGPT are rapidly changing how people find answers. Instead of browsing through links, users are getting direct summaries on AI. These 'zero-click' searches quietly erode the economics that built the modern internet. The number of users is growing fast. OpenAI CEO Sam Altman said in April that ChatGPT already has 'something like 10% of the world" in terms of users, pegging the number closer to 800 million, Forbes reported. Even Google seems to know it. It's giving AI answers, called AI Overviews, right at the top of the page. "What's changing is not that fewer people are searching the that more and more the answers to Google are being answered right on Google's page. That AI box at the top of Google is now absorbing that content that would have gone to the original content creators," Cloudflare CEO Matthew Prince said in a CNBC interview. Alphabet () , Google's parent company, isn't showing any cracks just yet. In April, the company posted first-quarter revenue of $90.23 billion, topping Wall Street expectations. Earnings per share came in at $2.81, far above the forecasted $ the backbone of Google's business, brought in $66.89 billion, accounting for nearly three-quarters of total revenue. Its 'Search and other' segment rose almost 10% year over year, hitting $50.7 billion. Meanwhile, Google's own AI tools are starting to show traction. AI Overviews now has 1.5 billion users per month, up from 1 billion in October, the company said. So far, the numbers suggest that AI isn't cannibalizing Google's business yet. Bank of America remains bullish on Alphabet stock. The firm reiterated a buy rating and a price target of $200, which implies a potential 15% upside from current levels, according to a recent research report. The firm said in May, Google's global average daily web visits held steady at 2.7 billion, unchanged from the previous month and down 2% from a year earlier. ChatGPT, meanwhile, saw a 3% month-over-month increase to 182 million, marking a 105% jump the U.S., Google traffic slipped 2% year-over-year to 524 million daily visits, while ChatGPT surged 112% over the same period to 26 million. Although Google has highlighted the growing reach of its AI Overviews, analysts are uncertain whether it's translating into more traffic. 'So far, we are not seeing a lift in Google traffic from AI Overviews expansion, though we think the search experience is much improved,' the analysts wrote. The competition is real. Google's global search share also edged down in May, falling 8 basis points month-over-month and 123 basis points year-over-year to 89.6%, according to Statcounter. Still, Bank of America analysts remain optimistic on Alphabet stock. "While ChatGPT's traffic continues to grow rapidly, we think Google remains well-positioned given its scale, multi-product reach, data assets, and robust monetization infrastructure," the analysts said. "AI can expand overall search monetization by better understanding the intent behind complex and long-tail queries that were previously hard to monetize," they added. Morningstar's Malik Ahmed Khan echoed that sentiment, saying Alphabet's diverse revenue streams and global exposure should cushion any hits, even as regulatory and AI risks mount, according to a May research report. Alphabet stock closed at $174.92 on June 6. The stock is down 8% unveil bold forecast for Alphabet stock despite ChatGPT threat first appeared on TheStreet on Jun 6, 2025 This story was originally reported by TheStreet on Jun 6, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
SmartRent Enhances Its Platform with AI Intelligence and Energy-Saving Features
SmartRent, Inc. (NYSE:SMRT), a top provider of smart community and operations solutions for the rental housing sector, has announced a major upgrade to its platform by adding an AI-powered intelligence layer and improved energy management tools. These enhancements are designed to help operators make better decisions that reduce utility waste, lower costs, and support environmental, social, and governance (ESG) objectives. A builder wearing a hard hat admiring a newly constructed smart home. The latest innovation, SMRT IQ, uses real-time data from connected devices to give teams comprehensive insights across their entire property portfolio, enabling quicker and smarter operational decisions. This update represents a significant shift for SmartRent, Inc. (NYSE:SMRT), moving beyond simple automation to delivering intelligent solutions that simplify data access and interpretation, allowing operators to take immediate action. Isaiah DeRose-Wilson, Chief Technology Officer at SmartRent, Inc. (NYSE:SMRT), made the following comment: "SMRT IQ marks a significant milestone in SmartRent's evolution. It delivers constant, real-time IoT-device level data and visibility into all aspects of property performance, enabling the decision-making process with insights that just weren't possible before. By combining that data with conversational AI, we're helping teams make smarter decisions faster and act with confidence at scale. It's further connecting teams to their communities, saving them time and improving business agility across the board." Unlike others that offer partial solutions, SmartRent, Inc. (NYSE:SMRT) provides a complete property operations platform tailored for rental housing. It integrates connected hardware, digital workflows, and built-in intelligence to automate tasks for owners, operators, and site teams, helping reduce operating costs while enhancing the resident experience within one unified system. While we acknowledge the potential of SMRT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio


Health Line
43 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.